Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone

Virology Journal

Volumn 7, Issue , 2010, Pages

  Chandra, Partha K ^a   Hazari, Sidhartha ^a   Poat, Bret ^a   Gunduz, Feyza ^a   Prabhu, Ramesh ^a   Liu, Gerald ^a   Burioni, Roberto ^b   Clementi, Massimo ^b   Garry, Robert F ^a   Dash, Srikanta ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HELICASE; IMMUNOGLOBULIN G1 ANTIBODY; NS3 HELICASE ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ARTICLE; CELL CULTURE; CLONE; DRUG EFFECT; GENE EXPRESSION SYSTEM; HEPATITIS C VIRUS; INFLUENZA VIRUS; NONHUMAN; REPLICON; STABLE EXPRESSION; SUPERNATANT; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; CELL LINE; CYTOPLASM; DOWN REGULATION; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HEPATITIS C; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; VIROLOGY;

ADENOVIRIDAE; CERCOPITHECINE HERPESVIRUS 1; HEPATITIS C VIRUS; ORTHOMYXOVIRIDAE;

CELL LINE; CYTOPLASM; DOWN-REGULATION; GENE EXPRESSION; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOGLOBULIN G; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 77953080993     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-118     Document Type: Article

References (43)

1. Hepatitis C, Fact Sheet No.164. Revised October 2000. World Health Organization (WHO), http://www.who.int/inf-fs/en/fact164.html
2. Diagnosis, management, and treatment of hepatitis C. DB Strader T Wright DL Thomas LB Seeff, Hepatology 2004 39 1147 1171 10.1002/hep.20119 15057920
3. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. KE Reed CM Rice, Curr Top Microbiol Immunol 2000 242 55 84 10592656
4. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. AD Kwong L McNair I Jacobson S George, Curr Opin Pharmacol 2008 8 522 531 10.1016/j.coph.2008.09.007 18835365
5. Specifically targeted antiviral therapy for hepatitis C virus. A Parfieniuk J Jaroszewicz R Flisiak, World J Gastroenterol 2007 13 5673 5681 17963291
6. The way forward in HCV treatment-finding the right path. MP Manns GR Foster JK Rockstroh S Zeuzem F Zoulim M Houghton, Nat Rev Drug Discov 2007 6 991 1000 10.1038/nrd2411 18049473
7. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. M Alt R Renz PH Hofschneider G Paumgartner WH Caselmann, Hepatology 1995 22 707 717 7657273
8. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. R Hanecak V Brown-Driver MC Fox RF Azad S Furusako C Nozaki C Ford H Sasmor KP Anderson, J Virol 1996 70 5203 5212 8764029
9. Oligonucleotide-based therapeutic options against hepatitis C virus infection. JB Trepanier JE Tanner C Alfieri, Antivir Ther 2006 11 273 287 16759043
10. Specific inhibition of hepatitis C virus expression by antisense oligdeoxynucleotides. In virto model for selection of target sequence. T Wakita JR Wands, J Biol Chem 1994 269 14205 14210 8188703
11. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. G Randall A Grakoui CM Rice, Proc Natl Acad Sci USA 2003 100 235 240 10.1073/pnas.0235524100 12518066
12. Small interfering RNA effectively inhibits protein expression and negative strand RNA synthesis from a full-length hepatitis C virus clone. R Prabhu P Vittal Q Yin E Flemington R Garry WH Robichaux S Dash, J Med Virol 2005 76 511 519 10.1002/jmv.20391 15977238
13. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. D Grimm MA Kay, Gene Ther 2006 13 563 575 10.1038/sj.gt.3302727 16453009
14. Therapeutic application of RNA interference for hepatitis C virus. T Watanabe T Umehara M Kohara, Adv Drug Deliv Rev 2007 59 1263 1276 10.1016/j.addr.2007.03.022 17822803
15. Inhibition of hepatitis C virus infection in cell culture by small interfering RNAs. C Chevalier A Saulnier Y Benureau D Fléchet D Delgrange F Colbère-Garapin C Wychowski A Martin, Mol Ther 2007 15 1452 1462 10.1038/sj.mt.6300186 17505476
16. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralizing epitopes. B Bartosch J Bukh JC Meunier C Granier RE Engle WC Blackwelder SU Emerson FL Cosset RH Purcell, Proc Natl Acad Sci USA 2003 100 14199 14204 10.1073/pnas.2335981100 14617769
17. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. R Burioni F Bugli N Mancini D Rosa C Di Campli G Moroncini A Manzin S Abrignani PE Varaldo M Clementi G Fadda, Virology 2001 288 29 35 10.1006/viro.2001.1014 11543655
18. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. R Burioni P Plaisant A Manzin D Roza V Delli Carri F Bugli L Solforosi S Abrignani PE Varaldo G Fadda M Clementi, Hepatology 1998 28 810 814 10.1002/hep.510280331 9731577
19. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. DX Johansson C Voisset AW Tarr M Aung JK Ball J Dubuisson MA Persson, Proc Natl Acad Sci USA 2007 104 16269 16274 10.1073/pnas.0705522104 17911260
20. Monoclonal antibody recognizing N-terminal epitope of hepatitis C virus nonstructural 5B inhibits viral RNA replication. SM Kang SH Choi CY Park MH Kim TK Kim JM Park MS Koh HJ Kang SB Hwang, J Viral Hepat 2008 15 305 313 10.1111/j.1365-2893.2007.00945.x 18307593
21. Specific targeting of hepatitis C virus core protein by an intracellular single-chain antibody of human origin. J Karthe K Tessmann J Li R Machida M Daleman D Haussinger T Heintges, Hepatology 2008 48 702 712 10.1002/hep.22366 18697213
22. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. ZY Keck TK Li J Xia M Gal-Tanamy O Olson SH Li AH Patel JK Ball SM Lemon SK Foung, J Virol 2008 82 6061 6066 10.1128/JVI.02475-07 18400849
23. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. JC Meunier RS Russell V Goossens S Priem H Walter E Depla A Union KN Faulk J Bukh S Emerson RH Purcell, J Virol 2008 82 966 973 10.1128/JVI.01872-07 17977972
24. Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. D Moradpour E Bieck T Hugle W Wels JZ Wu Z Hong HE Blum R Bartenschlager, J Biol Chem 2002 277 593 601 10.1074/jbc. M108748200 11641406
25. Functional characterization of fingers subdomain-specific monoclonal antibodies inhibiting the hepatitis C virus RNA-dependent RNA polymerase. A Nikonov E Juronen M Ustav, J Biol Chem 2008 283 24089 24102 10.1074/jbc. M803422200 18574240
26. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. AM Owsianka AW Tarr ZY Keck TK Li J Witteveldt R Adair SK Foung JK Ball AH Patel, J Gen Virol 2008 89 653 659 10.1099/vir.0.83386-0 18272755
27. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. A Owsianka AW Tarr VS Juttla D Lavillette B Bartosch FL Cosset JK Ball AH Patel, J Virol 2005 79 11095 11104 10.1128/JVI.79.17.11095-11104.2005 16103160
28. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. M Perotti N Nancini RA Diotti AW Tarr JK Ball A Owsianka R Adair AH Patel M Clementi R Burioni, J Virol 2008 82 1047 1052 10.1128/JVI.01986-07 17989176
29. Human monoclonal recombinant Fabs specific for HCV antigens obtained by repertoire cloning in phage display combinatorial vectors. P Plaisant R Burioni A Manzin L Solforosi M Candela A Gabrielli G Fadda M Clementi, Res Virol 1997 148 165 169 10.1016/S0923-2516(97)89904-9 9108620
30. Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone. R Prabhu N Khalap R Burioni M Clementi RF Garry S Dash, Am J Pathol 2004 165 1163 1173 15466383
31. Construction and characterization of an intracellular single-chain human antibody to hepatitis C virus non-structural 3 protein. D Sullivan U Mondelli M DT Curiel V Krasnykh G Mikheeva P Gaglio CB Morris S Dash MA Gerber, J Hepatol 2002 37 660 668 10.1016/S0168-8278(02)00270-2 12399234
32. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. DJ Schofield B Bartosch YK Shimizu T Allander HJ Alter SU Emerson FL Cosset RH Purcell, Hepatology 2005 42 1055 1062 10.1002/hep.20906 16250048
33. Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease. T Ueno S Misawa Y Ohba M Matsumoto M Mizunuma N Kasai K Tsumoto I Kumagai H Hayashin, J Virol 2000 74 6300 6308 10.1128/JVI.74.14.6300-6308.2000 10864639
34. Production and characterization of monoclonal antibody specific for NS3 helicase of hepatitis C virus. J Yang YF Lei W Yin SH Wei QX An X X. Lv XB Hu ZK Xu, Hybridoma (Larchmt) 2008 27 181 186 10.1089/hyb.2007.0557 18582211
35. Expression and targeting of intracellular antibodies in mammalian cells. S Biocca MS Neuberger A Cattaneo, EMBO J 1990 9 101 108 2153072
36. Humanized antibodies for antiviral therapy. MS Co M Deschamps RJ Whitley C Queen, Proc Natl Acad Sci USA 1991 88 2869 2873 10.1073/pnas.88.7.2869 1849279
37. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. T Wakita T Pietschmann T Kato T Date M Miyamoto Z Zhao K Murthy A Habermann HG Krausslich M Mizokami R Bartenschlager TJ Liang, Nat Med 2005 11 791 796 10.1038/nm1268 15951748
38. Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. S Hazari PK Chandra B Poat S Datta RF Garry TP Foster G Kousoulas T Wakita S Dash, Virology J 2010 7 36 10.1186/1743-422X-7-36
39. Production and characterization of a human recombinant monoclonal Fab fragment specific for Influenza A viruses. A Desogus R Burioni A Ingianni F Bugli R Pompei G Fadda, Clin Diagn Lab Immunol 2003 10 680 685 12853404
40. Simultaneous detection of HCV and HIV-1 by SYBR Green real time multiplex RT-PCR technique in plasma samples. D Gibellini F Gardini F Vitone P Schiavone G Furlini M Carla Re, Mol Cell Probes 2006 20 223 229 10.1016/j.mcp.2005.12.005 16537101
41. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. DN Frick, Curr Issues Mol Biol 2007 9 1 20 17263143
42. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. P Gallinari D Brennan C Nardi M Brunetti L Tomei C Steinkuhler R De Francesco, J Virol 1998 72 6758 6769 9658124
43. Structure-based mutational analysis of the hepatitis C virus NS3 helicase. CL Tai WC Pan SH Liaw UC Yang LH Hwang DS Chen, J Virol 2001 75 8289 8297 10.1128/JVI.75.17.8289-8297.2001 11483774